Price
Financials
Standalone, Rs crore| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 181 | 167 | 184 | 163 | 208 | 318 | 340 | 355 | 165 | 192 | 235 | 293 |
| Expenses | 119 | 112 | 131 | 119 | 139 | 194 | 200 | 234 | 111 | 146 | 163 | 195 |
| Operating Profit | 63 | 55 | 53 | 44 | 69 | 124 | 140 | 121 | 55 | 47 | 71 | 98 |
| OPM % | 35% | 33% | 29% | 27% | 33% | 39% | 41% | 34% | 33% | 24% | 30% | 33% |
| Other Income | 8 | -3 | 9 | 9 | 12 | 13 | 12 | 8 | 24 | 13 | 23 | 15 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 5 | 0 | 1 | 1 |
| Depreciation | 6 | 8 | 8 | 3 | 5 | 5 | 5 | 6 | 6 | 6 | 6 | 7 |
| Profit before tax | 64 | 44 | 54 | 49 | 77 | 132 | 147 | 123 | 69 | 54 | 87 | 106 |
| Tax % | 26% | 27% | 27% | 24% | 24% | 25% | 25% | 26% | 24% | 25% | 26% | 26% |
| Net Profit | 48 | 32 | 40 | 38 | 58 | 99 | 110 | 91 | 52 | 40 | 64 | 78 |
| EPS in Rs | 2.76 | 1.85 | 2.29 | 2.18 | 3.36 | 5.71 | 6.35 | 5.26 | 3.01 | 2.32 | 3.71 | 4.51 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|
| Sales | 538 | 499 | 683 | 721 | 712 | 1,030 | 947 | 886 |
| Expenses | 325 | 292 | 434 | 502 | 481 | 652 | 653 | 614 |
| Operating Profit | 214 | 207 | 249 | 219 | 231 | 378 | 294 | 271 |
| OPM % | 40% | 41% | 36% | 30% | 32% | 37% | 31% | 31% |
| Other Income | 6 | 9 | 19 | 24 | 18 | 46 | 69 | 76 |
| Interest | 7 | 5 | 3 | 1 | 0 | 0 | 6 | 6 |
| Depreciation | 18 | 20 | 22 | 25 | 28 | 18 | 24 | 25 |
| Profit before tax | 194 | 190 | 243 | 217 | 220 | 406 | 333 | 316 |
| Tax % | 25% | 26% | 25% | 26% | 26% | 25% | 25% | |
| Net Profit | 145 | 142 | 182 | 160 | 164 | 305 | 248 | 235 |
| EPS in Rs | 24,118.33 | 1,428.77 | 10.47 | 9.23 | 9.44 | 17.59 | 14.29 | 13.55 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 11% | 7% | 8% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | % | 14% | 10% | -28% | ||
| Compounded Profit Growth | % | 11% | 15% | -34% | ||
| Stock Price CAGR | % | % | % | -13% | ||
| Return on Equity | % | 26% | 24% | 19% |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 0.60 | 10 | 35 | 35 | 35 | 35 | 35 |
| Reserves | 198 | 330 | 487 | 647 | 811 | 1,098 | 1,325 |
| Borrowings | 74 | 52 | 19 | 5 | 3 | 21 | 44 |
| Other Liabilities | 92 | 142 | 173 | 176 | 211 | 263 | 238 |
| Total Liabilities | 364 | 534 | 713 | 862 | 1,059 | 1,418 | 1,641 |
| Fixed Assets | 107 | 139 | 156 | 151 | 172 | 300 | 316 |
| CWIP | 2 | 3 | 3 | 30 | 147 | 89 | 301 |
| Investments | 26 | 37 | 94 | 189 | 250 | 187 | 252 |
| Other Assets | 229 | 355 | 460 | 491 | 489 | 841 | 771 |
| Total Assets | 364 | 534 | 713 | 862 | 1,059 | 1,418 | 1,641 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 122 | 137 | 146 | 142 | 241 | 46 | 334 |
| Cash from Investing Activity | -45 | -61 | -76 | -147 | -264 | -35 | -276 |
| Cash from Financing Activity | -72 | -21 | -56 | -4 | -2 | -19 | -31 |
| Net Cash Flow | 5 | 55 | 14 | -10 | -24 | -8 | 28 |
| Free Cash Flow | 106 | 85 | 125 | 83 | 68 | -34 | 115 |
| CFO/OP | 80% | 66% | 70% | 92% | 109% | 36% | 151% |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 80 | 105 | 121 | 121 | 91 | 124 | 131 |
| Inventory Days | 120 | 253 | 133 | 137 | 151 | 209 | 157 |
| Days Payable | 90 | 128 | 72 | 58 | 35 | 70 | 48 |
| Cash Conversion Cycle | 110 | 231 | 183 | 199 | 206 | 262 | 240 |
| Working Capital Days | 55 | 89 | 103 | 120 | 92 | 157 | 136 |
| ROCE % | 58% | 53% | 35% | 30% | 40% | 26% |
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Jul 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 86.00% | 86.00% | 86.00% | 86.00% | 86.00% | 86.00% | 86.00% | 79.81% | 79.81% | 79.81% | 79.81% | 73.15% |
| FIIs | 2.93% | 2.01% | 2.02% | 2.18% | 1.10% | 2.28% | 1.97% | 1.83% | 1.14% | 0.89% | 0.40% | 0.63% |
| DIIs | 3.70% | 3.04% | 2.14% | 1.75% | 2.02% | 1.33% | 0.95% | 3.63% | 4.65% | 4.51% | 4.65% | 9.11% |
| Public | 7.37% | 8.97% | 9.83% | 10.06% | 10.87% | 10.38% | 11.08% | 14.74% | 14.41% | 14.80% | 15.14% | 17.11% |
| No. of Shareholders | 55,589 | 48,625 | 42,882 | 41,933 | 43,003 | 54,581 | 70,772 | 80,117 | 80,187 | 79,199 | 78,917 | 78,927 |
Fundamentals
Market Cap₹ 10,403 Cr.
Current Price₹ 550
Stock P/E44.3
Book Value₹ 78.4
ROCE26.1 %
ROE19.4 %
Dividend Yield0.22 %
Face Value₹ 2.00
Compounded Sales Growth (TTM)-28%
Compounded Profit Growth (TTM)-34%
Standalone figures.
Valuation
Market capRs 9,398 Cr
Enterprise valueRs 9,338 Cr
P/E (TTM)40.01x
Price to book13.79x
Price to sales10.61x
EV / EBITDA26.92x
EV / EBIT29.02x
EV / sales10.54x
Price to cash flow66.39x
Earnings yield2.50%
Profitability
Operating margin (excl. other income)30.39%
Operating margin (incl. other income)33.71%
EBITDA margin39.16%
Pre-tax margin35.63%
Net profit margin26.52%
Net margin, latest quarter26.70%
ROE26.60%
ROCE35.54%
ROA20.32%
ROE, 3-year average40.47%
ROCE, 3-year average49.15%
ROA, 3-year average27.00%
ROIC (approx.)38.30%
Tax rate26.12%
Other income / net worth3.52%
Growth
Sales growth (latest year)5.49%
Profit growth (latest year)-11.87%
Sales CAGR, 3 years10.24%
Profit CAGR, 3 years3.41%
Sales growth QoQ24.90%
Profit growth QoQ21.64%
Sales growth YoY (latest quarter)-17.38%
Profit growth YoY (latest quarter)-14.16%
Per share
EPS (TTM)Rs 13.54
EPS (latest year)Rs 9.23
EPS (latest quarter)Rs 4.51
EPS, 3-year averageRs 482.81
Book value per shareRs 39.29
Sales per shareRs 51.06
Cash flow per shareRs 8.16
Free cash flow per shareRs 6.63
Efficiency
Asset turnover0.84x
Fixed asset turnover4.77x
Inventory turnover3.22x
Inventory days113 days
Debtor days121 days
Debtors turnover3.01x
Creditor days48 days
Cash conversion cycle240 days
Working capital days136 days
Leverage
Total debtRs 5 Cr
Cash and bankRs 66 Cr
Net debtRs -61 Cr
Debt to equity0.01x
Net debt / EBITDA-0.17x
Interest coverage51.82x
Current ratio (filing 2026-03-31)4.21x
Quick ratio (filing 2026-03-31)3.38x
Trade payables (filing 2026-03-31)Rs 57 Cr
Owners' fund to total sources79.05%
Debt to assets0.57%
Cash flow
Cash from Operating Activity (latest year)Rs 142 Cr
Cash from Investing Activity (latest year)Rs -147 Cr
Cash from Financing Activity (latest year)Rs -4 Cr
Net Cash Flow (latest year)Rs -10 Cr
Free cash flow (latest year)Rs 115 Cr
FCFE (approx.: FCF + change in debt)Rs 101 Cr
Cash from ops / profit, 5 years0.86x
Sales to cash flow5.09x
Statement figures
Net sales (TTM)Rs 886 Cr
Net sales (latest year)Rs 721 Cr
Sales (latest quarter)Rs 293 Cr
Operating profit excl. other income (latest year)Rs 219 Cr
Operating profit (latest quarter)Rs 98 Cr
Other income (TTM)Rs 76 Cr
EBITDA (TTM)Rs 347 Cr
PBDT (TTM)Rs 341 Cr
Profit before tax (TTM)Rs 316 Cr
Tax (latest year)Rs 57 Cr
Net profit (TTM)Rs 235 Cr
Net profit (latest year)Rs 160 Cr
Net profit (latest quarter)Rs 78 Cr
Depreciation (TTM)Rs 25 Cr
Depreciation (latest quarter)Rs 7 Cr
Interest (TTM)Rs 6 Cr
Cost of goods sold (latest year)Rs 404 Cr
Total expenditure (latest year)Rs 502 Cr
Total income (latest year)Rs 745 Cr
Share capitalRs 35 Cr
ReservesRs 647 Cr
Shareholders' fundsRs 681 Cr
Total assetsRs 862 Cr
Net blockRs 151 Cr
Capital work in progressRs 30 Cr
InvestmentsRs 189 Cr
ReceivablesRs 239 Cr
InventoryRs 126 Cr
Other liabilitiesRs 176 Cr
Shares outstanding (crore)17.35
Ownership
Promoter holding73.15% (-6.66 in a year)
Computed by MarketFriction from the standalone statements. Returns use average balances.
P/E 40.0 is at the 33th percentile of its own 3.0-year range
(median 43.8, low 19.3, high 91.9).
P/B 13.79 is at the 11th percentile (median 24.16).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
| Period | BLUEJET | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | -5.5% | -2.8% | -2.7 pts |
| 1 month | -7.6% | -6.8% | -0.8 pts |
| 3 months | -2.6% | -7.6% | +5.1 pts |
| 6 months | +65.6% | +0.4% | +65.2 pts |
| 1 year | -18.5% | -9.9% | -8.6 pts |
| 2 years | +3.3% | -13.6% | +16.8 pts |
45 mutual fund schemes hold about ₹491 Cr.
Over three months 43 bought more and 1 sold (share counts, price move removed).
| Fund | Weight | Est. Cr | 3m shares |
|---|---|---|---|
| ICICI Pru Healthcare Fund- | 1.93% | 135 | +31% |
| ICICI Pru Value Fund | 0.13% | 76 | +100% |
| ICICI Pru Manufacturing Fund | 1.01% | 73 | +100% |
| UTI Small Cap Fund | 0.80% | 42 | +61% |
| Qsif Equity Long-Short Fund | 3.50% | 26 | +100% |
| Altiva Hybrid Long-Short Fund | 0.27% | 25 | +100% |
| Groww Multicap Fund | 1.58% | 23 | +15% |
| ICICI Pru MNC Fund | 1.06% | 19 | +100% |
| Groww Small Cap Fund | 2.29% | 18 | +36% |
| UTI Healthcare Fund | 0.99% | 14 | +100% |
| Motilal Oswal Contra Fund | 2.11% | 9 | +100% |
| ITI Large & Mid Cap Fund | 1.19% | 9 | +100% |
| Qsif Equity Ex-Top 100 Long-Short Fund | 1.20% | 5 | +100% |
| Nippon India Nifty Smallcap 250 Index Fund | 0.13% | 5 | +58% |
| SBI Nifty Smallcap 250 Index Fund | 0.13% | 2 | +58% |
| Motilal Oswal Nifty Smallcap 250 Index Fund | 0.13% | 2 | +59% |
| Qsif Hybrid Long-Short Fund | 0.61% | 1 | +100% |
| ICICI Pru Nifty Smallcap 250 Index Fund | 0.13% | 1 | +58% |
| HDFC NIFTY Smallcap 250 Index Fund | 0.13% | 1 | +58% |
| Nippon India Nifty 500 Equal Weight Index Fund | 0.19% | 1 | -5% |
| JioBlackRock Nifty Smallcap 250 Index Fund | 0.13% | 1 | +58% |
| Motilal Oswal Nifty 500 Index Fund | 0.01% | 0 | +54% |
| Edelweiss Nifty Smallcap 250 Index Fund | 0.13% | 0 | +58% |
| Qsif Active Asset Allocator Long-Short Fund | 0.14% | 0 | +100% |
| Groww Nifty Smallcap 250 Index Fund | 0.13% | 0 | +58% |
Red flags
F-score 4 of 8| explain | Share dilution Share count up 0% in a year, 173400% in three |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Jun 2026Sales ₹293 Cr -17.5% vs Jun 2025.
Net profit ₹78 Cr -14.3%.
Against our estimate for Jun 2026: sales +27.5%, profit +28.4% in line. Our estimate for Sep 2026: sales Rs 125 Cr, profit Rs 34 Cr (how).
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
| Ex-date | Action | Factor |
|---|---|---|
| 2026-09-11 | Dividend - Rs 1.20 Per Share | |
| 2025-09-19 | Dividend - Rs 1.20 Per Share | |
| 2024-09-17 | Dividend - Re 1 Per Share | |
| 2024-09-17 | Annual General Meeting |
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.
Quick answers
What is the market cap of Blue Jet Healthcare Ltd?
Blue Jet Healthcare Ltd (BLUEJET) has a market capitalisation of Rs 10,403 Cr. at the 2026-10-01 close.
What is the P/E ratio of Blue Jet Healthcare Ltd?
Blue Jet Healthcare Ltd trades at a P/E of 44.3 on trailing twelve-month profit, at the 2026-10-01 close.
What were Blue Jet Healthcare Ltd's latest quarterly results?
In the Jun 2026 quarter, Blue Jet Healthcare Ltd sales was Rs 293 Cr (-17.5% vs Jun 2025) and net profit was Rs 78 Cr.
What is the 52-week high and low of Blue Jet Healthcare Ltd?
The 52-week high is Rs 692.90 and the 52-week low is Rs 325.00.